Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL

Craig Moskowitz, Andrew D. Zelenetz, Tarun Kewalramani, Paul Hamlin, Simone Lessac-Chenen, Jane Houldsworth, Adam Olshen, Raju Chaganti, Stephen D Nimer, Julie Teruya-Feldstein

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

A number of prognostic factors affect outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted international prognostic index. In de novo DLBCL, the cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplantation-eligible patients undergoing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if were they prognostic in the salvage setting. Pre-treatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT, event-free or overall survival based on the cell of origin or any of the common pathologic markers examined. The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL.

Original languageEnglish
Pages (from-to)3383-3385
Number of pages3
JournalBlood
Volume106
Issue number10
DOIs
StatePublished - Nov 15 2005
Externally publishedYes

Fingerprint

Germinal Center
Lymphoma, Large B-Cell, Diffuse
Microarrays
Refractory materials
Chemotherapy
Immunohistochemistry
Tissue
Salvaging
Ifosfamide
Biopsy
Transplantation
Carboplatin
Etoposide
Stem cells
Drug Therapy
Stem Cell Transplantation
Microarray Analysis
Cells
Disease-Free Survival
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. / Moskowitz, Craig; Zelenetz, Andrew D.; Kewalramani, Tarun; Hamlin, Paul; Lessac-Chenen, Simone; Houldsworth, Jane; Olshen, Adam; Chaganti, Raju; Nimer, Stephen D; Teruya-Feldstein, Julie.

In: Blood, Vol. 106, No. 10, 15.11.2005, p. 3383-3385.

Research output: Contribution to journalArticle

Moskowitz, Craig ; Zelenetz, Andrew D. ; Kewalramani, Tarun ; Hamlin, Paul ; Lessac-Chenen, Simone ; Houldsworth, Jane ; Olshen, Adam ; Chaganti, Raju ; Nimer, Stephen D ; Teruya-Feldstein, Julie. / Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. In: Blood. 2005 ; Vol. 106, No. 10. pp. 3383-3385.
@article{5c073e665c534dca9d391bbbf8618476,
title = "Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL",
abstract = "A number of prognostic factors affect outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted international prognostic index. In de novo DLBCL, the cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplantation-eligible patients undergoing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if were they prognostic in the salvage setting. Pre-treatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT, event-free or overall survival based on the cell of origin or any of the common pathologic markers examined. The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL.",
author = "Craig Moskowitz and Zelenetz, {Andrew D.} and Tarun Kewalramani and Paul Hamlin and Simone Lessac-Chenen and Jane Houldsworth and Adam Olshen and Raju Chaganti and Nimer, {Stephen D} and Julie Teruya-Feldstein",
year = "2005",
month = "11",
day = "15",
doi = "10.1182/blood-2005-04-1603",
language = "English",
volume = "106",
pages = "3383--3385",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL

AU - Moskowitz, Craig

AU - Zelenetz, Andrew D.

AU - Kewalramani, Tarun

AU - Hamlin, Paul

AU - Lessac-Chenen, Simone

AU - Houldsworth, Jane

AU - Olshen, Adam

AU - Chaganti, Raju

AU - Nimer, Stephen D

AU - Teruya-Feldstein, Julie

PY - 2005/11/15

Y1 - 2005/11/15

N2 - A number of prognostic factors affect outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted international prognostic index. In de novo DLBCL, the cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplantation-eligible patients undergoing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if were they prognostic in the salvage setting. Pre-treatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT, event-free or overall survival based on the cell of origin or any of the common pathologic markers examined. The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL.

AB - A number of prognostic factors affect outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted international prognostic index. In de novo DLBCL, the cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplantation-eligible patients undergoing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if were they prognostic in the salvage setting. Pre-treatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT, event-free or overall survival based on the cell of origin or any of the common pathologic markers examined. The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=27744563281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744563281&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-04-1603

DO - 10.1182/blood-2005-04-1603

M3 - Article

C2 - 16091454

AN - SCOPUS:27744563281

VL - 106

SP - 3383

EP - 3385

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -